EU Commissions Backs New GSK Asthma Drug

Following the green light from health regulator European Medicines Agency, the European Commission is expected to decide on a final approval for GlaxoSmithKline’s (GSK) injectable asthma drug, Nucala, before the end of 2015.

The US Food and Drug Administration (FDA) is expected to give its decision on Nucala, which is being recommended for asthma patients who don't respond well to traditional inhalers, by Nov. 4. The monthly injection is also being tested for treatment of chronic obstructive pulmonary disease (COPD).

Analysts said the new product could help boost GSK's respiratory franchise as demand weakens for its asthma drug, Advair. In monetary terms, the value of this market is calculated to be potentially in the multi-billion dollar range.

GSK and other drugmakers including the British-Swedish company AstraZeneca, Switzerland’s Roche, Israeli’s Teva Pharmaceutical Industries and France’s Sanofi, are also developing drugs that take a more personalized approach to asthma care.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.